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BACKGROUND: The prevalence of chronic kidney disease, 
particularly in diabetic patients, is increasing rapidly throughout 
the world. Nowadays, many individuals in developing nations are 
suffering from diabetes which is one of the primary risk factors of 
chronic kidney disease.  
METHODS: Institution based cross-sectional study was conducted 
at the University of Gondar Hospital from February to April 2016. 
A total of 229 study participants were selected using systematic 
random sampling technique. Urine sample was collected for 
albumin determination by dipstick. The Simplified Modification of 
Diet in Renal Disease study equation was used to estimate 
glomerular filtration rate. Binary logistic regression model was 
used to identify risk factors.  
RESULTS: Of the total 229 study participants, 50.2% were 
females and the mean age was 47±15.7 years. Among study 
participants, the prevalence of chronic kidney disease (CKD) was 
found to be 21.8% (95% CI: 16% - 27%). Of all study participants, 
9(3.9%) had renal impairment (eGFR < 60 ml/min/ 1.73 m2) and 
46 (20.1%) had albuminuria. Older age (AOR: 5.239, 95% CI: 
2.255-12.175), systolic blood pressure ≥140mmHg (AOR: 3.633, 
95% CI: 1.597-8.265), type 2 diabetes mellitus (AOR: 3.751, 95% 
CI: 1.507-9.336) and longer duration of diabetes (AOR: 3.380, 
95% CI: 1.393-8.197) were independent risk factors of CKD.  
CONCLUSIONS: The study identified high prevalence (21.8%) of 
CKD among diabetic adults. CKD was significantly associated with 
older age, systolic blood pressure, type 2 DM and longer duration 
of DM. Thus, DM patients should be diagnosed for chronic kidney 
disease and then managed accordingly.   
KEYWORDS: Chronic kidney disease, Diabetes mellitus, 




Chronic kidney disease (CKD) is a progressive loss in renal function 
over a period of three months or years. Kidneys can get damaged 
from a physical injury or a disease like diabetes mellitus (DM) or 
high blood pressure. Once kidneys are damaged, they cannot filter
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blood or perform other activities. This is usually 
associated with a reduction in glomerular 
filtration rate (GFR) and proteinuria (1,2).  
CKD is a worldwide public health problem, 
both for the number of patients and cost of 
treatment involved. It was a cause of 409,000 and 
956,000 deaths in 1990 and 2013, respectively. Of 
those deaths, 46,000 (1990) and 173,000 (2013)  
were caused by CKD due to DM (3). Globally, 
diseases of the kidney and urinary tract together 
are the 12th cause of death and the 17th cause of 
disability (4). CKD affects around 10–13% of the 
general population (5). It has been estimated that 
more than 500 million individuals globally have 
CKD, regardless of the cause (6). In sub-Saharan 
Africa, CKD is a considerable health burden. 
CKD is at least 3-4 times more frequent in Africa 
than in developed world (7). 
       CKD is associated with adverse outcomes of 
kidney failure, cardiovascular disease (CVD), and 
premature death (5,8). The risk of cardiovascular 
mortality, kidney failure, kidney-disease 
progression, acute kidney injury, cognitive 
decline, anaemia, mineral and bone disorders, 
fractures  and hospitalizations are higher among 
patients with CKD than those with normal renal 
function (9,10). Many of the complications of 
CKD can be prevented or delayed by early 
detection and treatment (11).  
          Major risk factors for the development and 
progression of CKD are diabetes and 
hypertension. CKD due to diabetes and 
hypertension affects nearly 5-7% of the world 
population and is more common in developing 
countries and disadvantaged and minority 
populations (12). Diabetes causes 9.1-29.9% of 
the cases of end stage renal disease (ESRD) in 
various developing countries, and hypertension 
leads to 13-21% of the cases (13). Hypertension 
affects almost 25% of the adult population in 
Africa and is the cause of chronic kidney failure 
in 21% of patients on renal replacement therapy in 
South Africa. The prevalence of diabetic 
nephropathy is estimated to be 23.8% in Zambia, 
14%-16% in South Africa, 12.4% in Egypt, 9% in 
Sudan, and 6.1% in Ethiopia (7).  
 CKD is an important cause of death and 
disability worldwide, but awareness of the 
disorder remains low in many communities and 
among many healthcare providers (10). The 
prevalence of DM is increasing alarmingly in 
developing countries like Ethiopia (14). In 
parallel, CKD will increase even if studies did not 
show the exact magnitude particularly in the study 
area, Gondar. Therefore, this study was aimed to 
assess the prevalence of CKD and associated risk 
factors among DM patients attending at 
University of Gondar Hospital, Northwest 
Ethiopia. 
 
MATERIALS AND METHODS 
 
Population and study design: The study was 
conducted at the University of Gondar Hospital 
Chronic Illness Clinic, Gondar, Northwest 
Ethiopia. Adult (≥18 years) DM patients who 
volunteered to give informed written consent were 
included in the study. Pregnant, hospitalized, non-
fasting, febrile patients, and patients with HIV 
and CVD were excluded. Institution based cross-
sectional study was conducted from February to 
April 2016.  
 
Data collection: The sample size was calculated 
using single population proportion formula 
considering 18.2% CKD prevalence in Southern 
Ethiopia (15) and assumptions of 5% margin of 
error, 10% non-response rate and 95% level of 
confidence. Even though, 252 study participants 
were assumed to be included, only 229 
volunteered to give informed written consent to 
participate in the study. Study participants were 
selected by systematic random sampling 
technique.  
        Socio-demographic, clinical and 
anthropometric data were collected by nurses after 
the participants agreed to sign written consent. 
Height was measured using standiometer, and 
weight was recorded using a balace with  patients 
being bare-footed and wearing light clothes. Body 
mass index (BMI) was calculated as weight 
divided by height squared (kg/m2). Underweight, 
normal weight, overweight and obese were 
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classified as BMI <18.5, 18.5- 24.9, 25-29.9 and 
≥30, respectively. 
        Blood pressure was measured by nurses 
using an analogue sphygmomanometer and 
stethoscope. Measurements were taken from the 
upper arm while placing the hand at the heart 
level after the patients had been sitting for more 
than 5 minutes. Systolic blood pressure ≥140 
mmHg and/or diastolic blood pressure ≥90 mmHg 
or current uses of blood pressure-lowering 
medication were used to define hypertension (16). 
Considering their current fasting blood glucose 
(FBG) level, participants were classified as with 
good glycemic control (FBG <150 mg/dl) and 
poor glycemic control (FBG ≥150 mg/dl) (15). 
          Laboratory technologists collected blood 
and urine samples, and performed biochemical 
tests. Five milliliters of fasting venous blood 
sample was collected with standard venipuncture 
technique to separate serum. Mindray BS-200 
(Shenzen Mindray Bio-Medical electronics Co. 
Ltd, China) analyzer was used for biochemical 
analysis. Serum glucose, creatinine and urea level 
were measured using the enzymatic glucose 
oxidase, kinetic alkaline picrate and enzymatic 
glutamate-dehydrogenase (GLDH) methods, 
respectively. Ten milliliters of freshly voided 
urine was collected by clean and dry container. 
Then, urine albumin was determined by using 
dipsticks (COMBINA 11S, Human). Presence of 
albumin in the urine (from +1 to +4) was defined 
as albuminuria.   
          The glomerular filtration rate (GFR) was 
estimated using Modification of Diet in Renal 
Disease (MDRD) study equation  as follow: 186 × 
×  × 
(0.742 if female) x (1.212, if black) (17). CKD 
was defined incorporating both eGFR and 
albuminuria. Patients having CKD were classified 
into five stages according to the Kidney Disease: 
Improving Global Outcomes (KDIGO) 
classification system as follows: stage 1: 
albuminuria with eGFR of ≥90 ml/min/1.73 m2, 
stage 2: albuminuria with eGFR of 60-89 
ml/min/1.73 m2, stage 3: eGFR of 30-59 
ml/min/1.73 m2, stage 4: eGFR of 15-29 
ml/min/1.73 m2 and stage 5 (kidney failure): 
eGFR of <15ml/min/1.73 m2. Stage 3 was further 
classified into 3A (eGFR of 45–59.9 ml/min/1.73 
m2) and 3B (eGFR of 30–44.9ml/min/1.73 m2) 
(1). 
Data analysis: Data were checked, sorted, 
categorized and coded manually. Then, data were 
entered into EPI info version 3.5.3 and then 
transferred to SPSS version 20 for analysis. 
Bivariate and multivariate logistic regression 
models were used to assess associated risk factors. 
Variables with a p-value of ≤0.2 in the bivariate 
analysis were remained in the multivariate logistic 
regression model to control the effect of 
confounding variables and to identify independent 
risk factors of CKD. Both crude and adjusted 
odds ratios with their 95% confidence intervals 
(CI) were computed to measure the strengths of 
associations between variables. A p-value of 
<0.05 was considered as statistically significant.   
 
Ethics approval: Ethical clearance was obtained 
from Research and Ethical Review Committee of 
School of Biomedical and Laboratory Sciences, 
College of Medicine and Health Sciences, 
University of Gondar. Permission letter was also 
taken from the clinical dDirector of the hospital 
and head of the DM clinic. To ensure 
confidentiality of the study participants’ 
information, anonymous typing was applied so 
that the name of the participants and any identifier 
was not written on the questionnaire. Data were 
collected after full written consent had been 
obtained from each participant. Patients with 
abnormal test results were consulted to consult 





Socio-demographic and clinical characteristics: 
The mean age of the study participants was 
47±15.7 years. The majority, 184(80.3%), of the 
participants were ≤60 years old, 182(79.5%) were 
urban dwellers, 202(88.2%) were Orthodox 
Christianity followers and 130(56.8%) were 
married (Table 1).  
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Among the study participants, 119(52%) had type 
2 DM and 101(44.1%) had  hypertension. Family 
history of CKD was found in 30(13.1%) 
participants. The majority of the participants, 
133(58.1%), were classified as normal weight, 
216(94.3%) never smoked and 168(73.4%) had 










Characteristics Number Percent 
Age (year) 
 
≤60 184 80.3 
>60 45 19.7 
Sex Male 114 49.8 
Female 115 50.2 
Religion Orthodox 202 88.2 
Muslim 23 10.0 
Protestant 4 1.8 
Residence Urban 182 79.5 
Rural 47 20.5 
Marital status Single 35 15.3 
Married 130 56.8 
Widowed 43 18.8 
Divorced 21 9.2 
Educational status No education 95 41.5 
Primary school 64 27.9 
Secondary school 38 16.6 
Higher education and above 32 14.0 
Occupation Merchant 18 7.9 
Housewife 61 26.6 
Government employed 69 30.1 
Self-employed 22 9.6 
Farmer 42 18.3 
Others 17 7.4 
Income (Ethiopian birr)  
 
 
<1001 124 54.1 
1001-2000 47 20.5 
2001-3000 26 11.4 
3001-4000 11 4.8 
>4000 21 9.2 
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Table 2: Clinical and behavioral characteristics 
 
 
Prevalence of CKD: The estimated prevalence of 
CKD was 21.8% (95% CI: 16% - 27%). Of all the 
study participants, 9(3.9%) had renal impairment 
(eGFR < 60 mL/min/1.73m2) and 46 (20.1%) had 
albuminuria (Table 2). All of the participants who 
had renal impairment and the majority of the 
participants with albminuria (37/46, 80%) were 
type 2 DM patients (Table 3). 
 
Table 3: Prevalence and stages of CKD 
  
Stage Description eGFR (ml/min/1.73m2) N (%) 
1 Normal eGFR with albuminuria ≥90 9(3.9) 
2 Slightly decreased eGFR with albuminuria 60-89.9 32(14.0) 
3 Moderately decreased eGFR 30-59.9 8(3.5) 
      3A Mildly to moderately decreased eGFR 45-59.9 5(2.2) 
      3B Moderately to severely decreased eGFR 30-44.9 3(1.3) 
4 Severely decreased eGFR 15-29.9 0(0) 




eGFR: estimated glomerular filtration rate, N: number, %: percent 
Characteristics Number Percent 
Body mass index 
 
Underweight (< 18.5) 22 9.6 
Normal weight  (18.5-24.9) 133 58.1 
Overweight (25-29.9) 54 23.6 
Obese ( ≥30) 20 8.7 
Systolic  blood pressure <140 mmHg 163 71.2 
≥140 mmHg 66 28.8 
Diastolic blood pressure <90 mmHg 209 91.3 
 ≥90 mmHg 20 8.7 
Hypertension Present 101 44.1 
Absent 128 55.9 
Waist circumference Low risk  155 67.7 
High risk  74 32.3 
Types of diabetes Type 1 110 48.0 
Type 2 119 52.0 
Duration of diabetes <10 years  179 79.2 
≥10 years  50 21.8 
Family history of kidney disease Yes 30 13.1 
No 199 86.9 
Smoking habit Never smoked 216 94.3 
Smoker 4 1.7 
ex-smoker 9 3.9 
Alcohol consumption habit  Yes 61 26.6 
No 168 73.4 
Fasting blood sugar <150mg/dl 102 45.5 
≥150mg/dl 127 55.5 
Urea level Normal (≤40 mg/dl ) 215 93.9 
High (> 40mg/dl ) 14 6.1 
Urine albumin Negative 183 79.9 
Positive 46 20.1 
Chronic kidney disease Present  50 21.8 
Absent  179 78.2 
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Associated risk factors of CKD: In the bivariate 
analysis, older age, obesity, elevated systolic 
blood pressure (SBP), hypertension, increased 
waist circumference (WC), type 2 DM, longer 
duration of diabetes and family history of kidney 
disease were found to be significantly associated 
with CKD.  
 The multivariable logistic 
regression analysis showed that older age, 
elevated SBP, increased WC, type 2 DM, and 
longer duration of diabetes were independently 
associated with CKD. The odds of CKD was 
5.239 (AOR: 5.239, 95% CI: 2.255-12.175) times 
higher among DM patients aged >60 years 
compared with DM patients ≤60 years of age. 
Patients having SBP ≥140mmHg were 3.633 
(AOR: 3.633, 95% CI: 1.597-8.265) times more 
likely to develop CKD than having SBP 
<140mmHg. Furthermore, patients with type 2 
DM and longer duration of diabetes were 3.751 
(AOR: 3.751, 95% CI: 1.507-9.336) and 3.380 
(AOR: 3.380, 95% CI: 1.393-8.197) times more 
likely to be affected by CKD than counterparts, 
respectively (Table 4).   
 
Table 4: Factors associated with CKD  
 
Variables          CKD  COR (95% CI) P-value  AOR (95% CI) P-value  
Yes No 
N (%) N (%) 
Age ≤60years 23(10) 161(70.3) 1.00  1.00  
>60years 27(11.8) 18(7.9) 10.5(5.013-21.992) 0.000 5.239(2.255-12.175)  0.000 
Sex Male 20(8.7) 94(41) 1.00    
Female 30(13.1) 85(37.1) 1.659(0.877-3.138) 0.120   
BMI ≤24.9 32(14) 123(53.7) 1.00  1.00  
25-29.9 9(3.9) 45(19.7)  0.769(0.340-1.736) 0.527 0.226(0.067-0.758) 0.016  
≥30 9(3.9) 11(4.8) 3.145(1.201-8.238) 0.02  0.992(0.255-3.860) 0.991 
Systolic BP <140mmHg 23(10) 140(61.1) 1.00  1.00  
≥140mmHg 27(11.8) 39(17) 4.214(2.179-8.151) 0.000 3.633(1.597-8.265) 0.002 
Diastolic BP <90 mmHg 44(19.2) 165(72.1) 1.00    
≥90 mmHg 6(2.6) 14(6.1) 1.607(0.584-4.424) 0.358   
Hypertension Present 36(15.7) 65(28.4) 4.51(2.266-8.977) 0.000   
Absent 14(6.1) 114(49.8) 1.00    
WC Low risk 24(10.5) 131(52.7) 1.00    
High risk 26(11.4) 48(21) 2.957(1.550-5.640) 0.001 3.430(1.212-9.704) 0.020 
Types of DM Type1 9(3.9) 101(44.1) 1.00  1.00  
Type2 41(17.9) 78(34.1) 5.899(2.705-12.863) 0.000 3.751(1.507-9.336) 0.004 
Duration of DM <10years 30(13.1) 149(65.1) 1.00  1.00  
≥10years 20(8.7) 30(13.1) 3.311(1.663-6.591) 0.001 3.380(1.393-8.197) 0.007 
FBS <150mg/dl 17(7.4) 85(37.1) 1.00    
≥150mg/dl 33(14.4) 94(41) 1.755(0.912-3.378) 0.092   
FH-KD Yes 11(4.8) 19(8.3) 2.375(1.045-5.398) 0.039   
No 39(17) 160(69.9) 1.00    
Alcohol 
consumption 
Yes 9(3.9) 52(22.7) 0.536(0.243-1.182) 0.122   
No 41(17.9) 127(55.5) 1.00    
AOR: Adjusted odds ratio, BMI: Body mass index, BP: Blood pressure, CKD: Chronic kidney disease, COR: Crude odds ratio, 
DM: Diabetes mellitus, FBS: Fasting blood sugar, FH-KD: Family history of kidney disease, N: Number, P: P-value, WC: Waist 
circumference, %: percent, 1.00: Reference group. 
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This study has assessed the prevalence and risk 
factors of CKD among diabetic adults at 
University of Gondar Hospital using an estimated 
glomerular filtration rate (eGFR) and urine 
albumin according to KDIGO guideline (1). The 
prevalence of CKD was 21.8% (95% CI: 16% - 
27%). Of all our study participants, 9(3.9%) had 
renal impairment (eGFR < 60 mL/min/1.73m2) 
and 46 (20.1%) had albuminuria (Table 2). All of 
the participants who had renal impairment and of 
the  with albminuria (37/46, 80%) were type 2 
DM patients. Nine (3.9%), 32(14.0%), 8(3.5%), 
and 1(0.4%) DM patients had an estimated GFR 
of ≥90 ml/min/1.73m2 (stage 1), 60–89.9 
ml/min/1.73m2 (stage 2), 30-59.9 ml/min/1.73m2 
(stage 3) and <15 ml/min/1.73 m2 (stage 5), 
respectively (Table 3).  
          Our estimate prevalence of CKD was lower 
than reports from Spain (27.9%) (18), Netherlands 
(28%) (19), UK (31%) (20), Mediterranean area 
(34.1%) (21), USA (39.6%) (22) and Japan 
(42.3%) (23). This difference in CKD prevalence 
might be because of the differences in case-mix 
(some of the studies included both type 1 and type 
2 DM patients but others included only type 2 
DM patients), creatinine and albumin assays, 
sample size and ethnic variations.    
          This study found a significant association 
between CKD and older age (AOR: 5.239, 95% 
CI: 2.255-12.175). This result is consistent with 
other studies’ outputs in various areas (18, 22, 24-
26). As age increases, there is progressive loss of 
nephrons and decreased renal blood flow, which 
leads to CKD (27). It is reported that findings of 
renal insufficiency (eGFR <60 mL/min/1.73 m2) 
and albuminuria become more prevalent in older 
age (28). Similarly, another study reported that 
individuals aged ≥65 years had 101.5 and 2.5 
times greater chance of developing renal 
insufficiency and proteinuria compared to their 
counterparts, respectively (29). Thus, screening of 
CKD in old age group is an important strategy to 
take an appropriate intervention.    
           CKD was independently associated with 
type 2 DM (AOR: 3.751, 95% CI: 1.507-9.336) 
and longer duration of DM (AOR: 3.380, 95% CI: 
1.393-8.197) in our study subjects. This 
corresponds with the findings of several studies 
which reported that the likelihood of developing 
CKD was greater among patients with longer 
duration of diabetes (24,30,31). CKD is estimated 
to affect ~50% patients with type 2 DM. 
Improvement in cardiovascular survival in patient 
with type 2 DM has contributed to patient 
surviving longer, allowing sufficient time to 
develop renal disease (32). However, CKD was 
not independently associated with type 2 DM in 
Japanese study (23).  
           According to our study, elevated SBP 
(AOR: 3.633, 95% CI: 1.597-8.265) was a risk 
factor for CKD. This was in agreement with other 
related studies, in which elevated SBP was 
independently associated with CKD (18, 33). The 
beneficial effects of controlling blood pressure 
(BP) and using antihypertensive agents for kidney 
function in diabetics has been described in current 
guidelines, which points out that control of BP 
reduce the rate of progression of renal disease in 
diabetes (34,35). 
         Obesity was not independently associated 
with CKD in our study. However, it was 
associated by bivariate analysis (COR: 3.145, 
95% CI: 1.201-8.238). In addition, increased WC 
(AOR: 3.430, 95% CI: 1.212-9.704) was 
independently associated with CKD in this study. 
Other similar studies reported as obesity was 
independent risk factor of CKD (36,37). This 
variation might be due to differences in lifestyles 
such as dietary habit, sedentary way of life and 
physical activities. In addition, our few sample 
size may affect the statistical tool to show the 
association between obesity and CKD. Obesity is 
associated with renal damage leading to 
albuminuria and poor outcomes of chronic kidney 
disease,  pointing to the need for prevention 
(38,39).  
        Single evaluation of eGFR and urine albumin 
may inflate the prevalence of CKD because of 
acute kidney infection and creatinine variability. 
We used dipstick method to measure urine 
albumin, and we were unable to calculate urine 
albumin-to-creatinine ratio to determine 
albuminuria. In addition, our sample size was 
relatively small and associations between 
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different severity levels of CKD with risk factors 
have not been confirmed. Despite these, the 
results of this study are important in raising 
awareness of the community regarding CKD 
among DM patients at the study setting.  
        In conclusion, the present study identified 
high prevalence of chronic kidney disease among 
diabetic adults. Older age, elevated systolic blood 
pressure, increased waist circumference, type 2 
diabetes mellitus, and longer duration of diabetes 
were independently associated with chronic 
kidney disease. Estimated glomerular filtration 
rate and albuminuria should be determined for 
diabetes mellitus patients at a regular interval of 
time for earlier diagnosis of chronic kidney 




BMI: Body Mass Index; BP: Blood Pressure; 
CKD: Chronic Kidney Disease; CVD: 
Cardiovascular Disease; DBP: Diastolic Blood 
Pressure; DM: Diabetes Mellitus; eGFR: 
estimated Glomerular Filtration Rate; ESRD: 
End-Stage Renal Disease; GFR: Glomerular 
Filtration Rate; KDIGO: Kidney Disease 
Improving Global Outcome; MDRD: 
Modification of Diet in Renal Disease; SBP: 
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